Evidence for the presence of NK1 and NK3 receptors on cholinergic neurones in the guinea-pig ileum.
In a guinea-pig ileum longitudinal muscle preparation, substance P (SP) (> or = 6 nM) caused an initial contraction followed by a sustained plateau contraction of about 20-50% of the initial response. This plateau contraction is caused by the SP-induced activation of cholinergic motoneurones which contract the smooth muscles by the released acetylcholine (ACh). We investigated the contribution of neurokinin NK1 and NK3 receptors during this 'plateau phase' of contraction. The plateau contraction induced by SP (60 nM) was significantly reduced by the NK1 receptor antagonist CP-96,345 (200 nM) added 5 min after SP, but was not affected by its inactive enantiomer CP-96,344 (200 nM). The NK1 receptor antagonist CP-99,994 (100 nM) significantly reduced the plateau contraction induced by SP (60 nM and 600 nM) and that induced by the NK1 receptor agonist substance P-O-methylester (SPOMe; 100 nM). CP-99,994 (100 nM), however did not affect the plateau contraction induced by the NK3 receptor agonist [Asp5,6, MePhe8]-SP(5-11) (100 nM). The plateau contraction induced by SP (600 nM) was not affected by the NK3 receptor antagonist SR-142,801 (100 nM), added 5 min after SP. Pre-incubation of the ileum with SR-142,801 (100 nM) 30 min prior to the addition of SP (600 nM) also had no significant effect on the plateau contraction. However, it significantly reduced the ileal contraction in the first minutes after the initial spasmogenic contraction. We suggest that SP induces the plateau contraction of the guinea-pig ileum longitudinal muscle mainly by the activation of NK1 receptors on cholinergic neurones.
Legat
F J
FJ
Department of Experimental and Clinical Pharmacology, University of Graz, Austria.
Althuber
P
P
Maier
R
R
Griesbacher
T
T
Lembeck
F
F
D000818:Animals; D002799:Cholinergic Fibers / Q000502:physiology*; D006168:Guinea Pigs; D007082:Ileum / Q000378:metabolism*; D009119:Muscle Contraction / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology*; D018040:Receptors, Neurokinin-1 / Q000187:drug effects*; D018042:Receptors, Neurokinin-3 / Q000187:drug effects*; D013997:Time Factors
D010880:Piperidines; D018040:Receptors, Neurokinin-1; D018042:Receptors, Neurokinin-3; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine